Page last updated: 2024-11-09

p5091

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

P5091: inhibits ubiquitin-specific protease 7; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2819993
CHEMBL ID2159495
SCHEMBL ID2681288
MeSH IDM0579142

Synonyms (43)

Synonym
1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone
LKZLGMAAKNEGCH-UHFFFAOYSA-N ,
CHEMBL2159495 ,
bdbm50393437
S7132
1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone
882257-11-6
CS-1445
p005091
HY-15667
p5091
p-5091
1-[5-[(2,3-dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone
SCHEMBL2681288
p 005091
p 5091
cyto5d7
1-(5-((2,3-dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one
AC-32692
AKOS024458314
c12h7cl2no3s2
1-{5-[(2,3-dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one
DTXSID90384841
1-[5-[(2,3-dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone
mfcd00123202
1-[5-(2,3-dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone
CCG-240421
HMS3653E09
p005091(p5091)
SW219710-1
FT-0714931
BCP07750
1-(5-((2,3-dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone
p5091 (p005091)
EX-A2120
BS-17872
1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone
SB19505
p-05091
HMS3743M19
C76908
NCGC00379189-01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)IC50 (µMol)4.20000.13004.04628.0000AID1491542; AID694815
Ubiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)IC50 (µMol)4.30004.30006.50008.7000AID694816
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)EC50 (µMol)6.10004.20005.46678.0000AID1195671; AID1195672
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
transcription-coupled nucleotide-excision repairUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
DNA alkylation repairUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein ubiquitinationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of protein stabilityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of circadian rhythmUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of gluconeogenesisUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
rhythmic processUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein stabilizationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of DNA-binding transcription factor activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
symbiont-mediated disruption of host cell PML bodyUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of signal transduction by p53 class mediatorUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of TORC1 signalingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of telomere cappingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of retrograde transport, endosome to GolgiUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
base-excision repairUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
DNA damage responseUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
response to xenobiotic stimulusUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
positive regulation of cell growthUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
cellular response to UVUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of apoptotic processUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of DNA-templated transcriptionUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
p53 bindingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
K48-linked deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
WD40-repeat domain bindingUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
PML bodyUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
chromosomeUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nuclear bodyUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein-containing complexUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
SCF ubiquitin ligase complexUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1491542Inhibition of full-length recombinant USP7 (unknown origin) expressed in Sf9 cells using Ub-EKL as substrate preincubated for 30 mins followed by substrate addition by fluorescence based assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
AID1882259Cytotoxicity against human multiple myeloma cells by WST-1 assay2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1195672Inhibition of USP7 in multiple myeloma cells (unknown origin) by immunohistochemistry2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Inhibiting the deubiquitinating enzymes (DUBs).
AID694826Cytotoxicity against human HCT116 cells after 72 hrs2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID1195671Inhibition of USP7 (unknown origin) by Ub-CHOP reporter assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Inhibiting the deubiquitinating enzymes (DUBs).
AID694815Inhibition of recombinant USP7 expressed in Sf9 cells by Ub-CHOP reporter assay2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694819Inhibition of caspase 3 using DEVD-Rh110 as substrate incubated for 30 mins prior to substrate addition by fluorimetric analysis2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694816Inhibition of USP47 by Ub-CHOP reporter assay2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694818Metabolic stability of the compound in rat plasma assessed as compound remaining at 1 uM after 3 hrs2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694817Chemical stability of the compound assessed as GSH adduct formation at 133 uM2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (62.50)24.3611
2020's9 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.19 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index1.71 (0.95)

This Compound (28.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]